COEP שולי רווחיות גולמית coeptistx.com

COEP (Coeptis Therapeutics, Inc.) - סמל מסחרי של החברה

The speculative status of Coeptis Therapeutics (COEP) is driven by the early stage of NK-therapy development. However, the potential for pricing power in oncohematology is high due to unique anti-leukemia platforms, while scientific alliances with medical centers are accelerating the search for treatments. Analyzing the data snapshot on the GURU.Markets chart, the median gross margin exhibits volatility, with the current level sitting around -207.80.

Coeptis Therapeutics (COEP) - שולי רווח גולמי מ-28.04.2023 עד 09.05.2026

פילוחי מדדים מקיפים ואנליטיקה עבור Coeptis (COEP)

- שווי מניות ותחזית קונצנזוס למחירים:
ניתוח מסכם של החברה:Coeptis Therapeutics - COEP
מוצר סדרתי של Coeptis Therapeutics Inc.

Gross margin determines the portion of revenue remaining after covering direct production costs, serving as a key metric of the issuer's operational efficiency and pricing power. By analyzing the gross profit margin, an investor can see the resilience of Coeptis Therapeutics (COEP), whose US-based localization and development of blood cancer therapies minimize external risks, confirming the fundamental quality and defensive qualities of the business model.